
|Videos|May 18, 2023
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
The Oncology Brothers are joined by Virginia Kaklamani, MD, DSc, who provides an overview of the EMERALD trial design and use of elacestrant in ER+, HER2- advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
2
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
5


























